Format

Send to

Choose Destination
J Endocr Soc. 2017 Mar 15;1(4):359-369. doi: 10.1210/js.2017-00053. eCollection 2017 Apr 1.

The Use of Resveratrol as an Adjuvant Treatment of Pain in Endometriosis: A Randomized Clinical Trial.

Author information

1
Postgraduate Program in Health Science: Gynecology and Obstetrics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil, 90035-903.
2
Department of Obstetrics and Gynecology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil, 90035-903.
3
Clínica Mulher, Porto Alegre, Rio Grande do Sul, Brazil, 90570-060.
4
Department of Obstetrics and Gynecology, Greenville Health System, Greenville, South Carolina.

Abstract

Context:

Resveratrol has been used for the treatment of endometriosis.

Objective:

To compare resveratrol (40 mg/d) with monophasic contraceptive pill (COC) to COC with placebo for the reduction of pain scores.

Design:

A randomized clinical trial.

Setting:

University Hospital.

Patients:

Women (ages 20 to 50) with laparoscopic diagnosis of endometriosis were eligible for the study. Exclusion criteria: pregnancy, allergy to resveratrol, or contraindications to COC, use of agonists of gonadotropin release hormone or danazol in the last month, or had used depot medroxyprogesterone acetate or Mirena®.

Intervention:

Subjects were randomized using a computer-generated randomization list to receive COC for 42 days to be taken with identical capsules containing 40 mg of resveratrol or placebo in coded bottles (1:1 ratio). Allocation was concealed in coded, sequenced, opaque-sealed envelopes.

Main Outcome:

Median pain scores measured with a visual analog scale on day 42.

Results:

Between 18 June and 6 November 2015, 44 subjects were enrolled. Mean [95% confidence interval (CI)] pain scores on day 0 were 5.4 (4.2 to 6.6) in the placebo group and 5.7 (4.8 to 6.6) in resveratrol groups. After treatment, pain values were [3.9 (2.2 to 5); n = 22] and [3.2 (2.1 to 4.3); n = 22] in the placebo and resveratrol groups, respectively (P = 0.7; Mann-Whitney U test). Median (95% CI) difference between groups was 0.75 (-1.6 to 2.3).

Conclusion:

Resveratrol is not superior to placebo for treatment of pain in endometriosis.

KEYWORDS:

endometriosis; pain; resveratrol

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center